$8.74
0.63[7.77%]
At close: Apr 17
$8.74
0[0.00%]
After Hours: 1:54AM EDT
XBiotech
(NASDAQ:XBIT)Latest News for XBiotech Stock (NASDAQ:XBIT)
XBiotech Stock (NASDAQ: XBIT)
Categories: All
Monday, January 22, 2024
Tuesday, September 26, 2023
Tuesday, September 05, 2023
Wednesday, August 30, 2023
Tuesday, August 08, 2023
Monday, May 22, 2023
Wednesday, May 17, 2023
- Why Doximity Shares Are Trading Lower By 8%? Here Are Other Stocks Moving In Wednesday's Mid-Day SessionLisa Levin - May 17, 2023, 12:51PM
- XBiotech shares are trading higher after the company commenced a tender offer to purchase up to $80 million worth of its shares.Benzinga Newsdesk - May 17, 2023, 10:12AM
- Dow Jumps Over 100 Points; US Housing Starts Rise In AprilLisa Levin - May 17, 2023, 9:45AM
- XBiotech Commences Tender Offer To Purchase Up To $80M Worth Of Its Shares At Price Not Greater Than $4.00 Nor Less Than $3.80 Per ShareBenzinga Newsdesk - May 17, 2023, 9:11AM
Monday, April 17, 2023
Monday, November 28, 2022
Thursday, October 20, 2022
Thursday, October 13, 2022
Thursday, September 22, 2022
Tuesday, September 20, 2022
Monday, September 19, 2022
Wednesday, August 31, 2022
Monday, August 29, 2022
Monday, August 22, 2022
Friday, August 19, 2022
Monday, August 01, 2022
Thursday, July 14, 2022
Tuesday, June 21, 2022
Thursday, June 02, 2022
Tuesday, May 24, 2022
Monday, May 16, 2022
Friday, May 06, 2022
- XBiotech Sponsored Study Titled 'Natrunix Versus Methotrexate in Rheumatoid Arthritis' Posted To ClinicalTrials.gov; Study Not Yet RecruitingBenzinga Newsdesk - May 6, 2022, 11:00AM
- XBiotech Sponsored Study Titled 'Natrunix or Placebo in Combination With Methotrexate in Rheumatoid Arthritis' Posted To ClinicalTrials.gov; Study Not Yet RecruitingBenzinga Newsdesk - May 6, 2022, 11:00AM
Friday, April 29, 2022
Thursday, April 28, 2022
- 12 Health Care Stocks Moving In Thursday's Intraday SessionBenzinga Insights - Apr 28, 2022, 3:18PM
- Why Are XBiotech Shares Trading Higher TodayVandana Singh - Apr 28, 2022, 2:53PM
- Xbiotech Announces French National Agency Approval And National Cancer Institute Funding To Support Phase I/II/III Clinical Study For Natrunix In Combination With Trifluridine/Tipiracil For Treatment Of Metastatic Colorectal CancerBenzinga Newsdesk - Apr 28, 2022, 9:08AM